Is NRIX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Bexobrutideg registrational path, with revenue (q3 fy2026, quarter ended aug 31 2026) at ~$673.1 million (~$653.2 million Roche license revenue). The bear case rests on as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.60 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. Analysts covering it are spread from $25.00 to $45.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.60 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $25.00, +2.4% from the $24.42 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Bexobrutideg registrational path. The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. The most optimistic analyst target on NRIX is $45.00, +84.3% from the $24.42 price. That figure is only reachable if this thesis works close to its best case.

As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.60 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. The roughly $1.1 billion cash position eases near-term funding pressure, and the stock's 149% one-year gain means more good news is already in the price. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected registrational path could sharply reduce the valuation. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation. The most pessimistic published target is $25.00, +2.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal m

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Bexobrutideg registrational path) stalling in the reported numbers rather than in the narrative, the risk above (as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.60 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Nurix is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines, drugs that recruit the cell's natural disposal system to destroy disease-causing proteins. Its focus spans cancer plus autoimmune and inflammatory diseases, led by the oral BTK degrader bexobrutideg.

Not on a recurring basis. In its fiscal third quarter (ended August 31, 2026) Nurix reported about $673.1 million of revenue and net income of roughly $549.8 million, but that came almost entirely from license revenue under the new Roche collaboration. In the prior quarters it lost about $87-90 million each, and analysts expect a loss of about $1.60 per share in fiscal 2027.

Bexobrutideg (NX-5948) is Nurix's lead drug candidate, an investigational oral, brain-penetrant degrader of BTK. It is being studied in the registrational Phase 2 DAYBreak CLL-201 trial in relapsed or refractory chronic lymphocytic leukemia, and a Phase 3 confirmatory study against pirtobrutinib (DAYBreak CLL-306) enrolled its first patient by October 2026.